Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1207-1213

  De Stefano, Alfonso ^a   Carlomagno, Chiara ^a   Pepe, Stefano ^a   Bianco, Roberto ^a   De Placido, Sabino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Arterial hypertension; Bevacizumab; Metastatic colorectal cancer; Predictive marker

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HYPERTENSION; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PELVIS CANCER; PERITONEUM METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 82455166762     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1604-1     Document Type: Article

References (33)

1. A Jemal R Siegel J Xu E Ward 2010 Cancer statistics, 2010 CA Cancer J Clin 60 5 277 300 10.3322/caac.20073 20610543 10.3322/caac.20073
2. N Ferrara KJ Hillan HP Gerber W Novotny 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 5 391 400 10.1038/nrd1381 15136787 10.1038/nrd1381 1:CAS:528:DC%2BD2cXktlCrt78%3D (Pubitemid 38618122)
3. F Kabbinavar HI Hurwitz L Fehrenbacher NJ Meropol WF Novotny G Lieberman S Griffing E Bergsland 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 1 60 65 12506171 10.1200/JCO.2003.10.066 1:CAS:528:DC%2BD2cXpsVWru7Y%3D
4. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2335 2342 10.1056/NEJMoa032691 15175435 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
5. LB Saltz S Clarke E Diaz-Rubio W Scheithauer A Figer R Wong S Koski M Lichinitser TS Yang F Rivera F Couture F Sirzen J Cassidy 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 12 2013 2019 10.1200/JCO.2007.14.9930 18421054 10.1200/JCO.2007.14.9930 1:CAS:528:DC%2BD1cXlvFaqs7g%3D
6. G Masi F Loupakis L Salvatore L Fornaro C Cremolini S Cupini A Ciarlo F Del Monte E Cortesi D Amoroso C Granetto G Fontanini E Sensi C Lupi M Andreuccetti A Falcone 2010 Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11 9 845 852 10.1016/S1470-2045(10)70175-3 20702138 10.1016/S1470-2045(10)70175-3 1:CAS:528:DC%2BC3cXhtFWqsr%2FF
7. BJ Giantonio PJ Catalano NJ Meropol PJ O'Dwyer EP Mitchell SR Alberts MA Schwartz AB Benson 3rd 2007 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 12 1539 1544 10.1200/JCO.2006.09.6305 17442997 10.1200/JCO.2006.09.6305 1:CAS:528:DC%2BD2sXlsVyntbc%3D (Pubitemid 46733080)
8. KA Lyseng-Williamson DM Robinson 2006 Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer BioDrugs 20 3 193 195 16724868 10.2165/00063030-200620030-00007 1:CAS:528:DC%2BD2sXhtV2rtrvE
9. E Van Cutsem F Rivera S Berry A Kretzschmar M Michael M DiBartolomeo MA Mazier JL Canon V Georgoulias M Peeters J Bridgewater D Cunningham 2009 Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 11 1842 1847 10.1093/annonc/mdp233 19406901 10.1093/annonc/mdp233
10. ML Maitland 2006 Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway J Clin Oncol 24 18S 2035
11. BI Levy G Ambrosio AR Pries HA Struijker-Boudier 2001 Microcirculation in hypertension: a new target for treatment? Circulation 104 6 735 740 11489784 10.1161/hc3101.091158 1:STN:280:DC%2BD3MvktlaqtQ%3D%3D (Pubitemid 32738532)
12. F Feihl L Liaudet B Waeber BI Levy 2006 Hypertension: a disease of the microcirculation? Hypertension 48 6 1012 1017 10.1161/01.HYP.0000249510.20326.72 17060505 10.1161/01.HYP.0000249510.20326.72 1:CAS:528:DC%2BD28XhtFymtL7J (Pubitemid 44772698)
13. AD Ruedemann 1937 A micro-camera for visualization of conjunctival vessels Trans Am Ophthalmol Soc 35 419 428 16693136 1:STN:280: DC%2BD28zis1ShsA%3D%3D
14. JM Sullivan RL Prewitt JA Josephs 1983 Attenuation of the microcirculation in young patients with high-output borderline hypertension Hypertension 5 6 844 851 6654450 1:STN:280:DyaL2c%2Fos1KrtQ%3D%3D (Pubitemid 14214817)
15. EH Serne RO Gans JC ter Maaten GJ Tangelder AJ Donker CD Stehouwer 2001 Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction Hypertension 38 2 238 242 11509483 1:CAS:528:DC%2BD3MXmtFGnur8%3D (Pubitemid 34224751)
16. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 783 792 10.1056/NEJM200103153441101 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
17. J Baselga 2001 Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials Oncology 61 Suppl 2 14 21 11694783 10.1159/000055397 1:CAS:528:DC%2BD3MXovFWjsL0%3D (Pubitemid 33033420)
18. F Di Fiore F Blanchard F Charbonnier F Le Pessot A Lamy MP Galais L Bastit A Killian R Sesboue JJ Tuech AM Queuniet B Paillot JC Sabourin F Michot P Michel T Frebourg 2007 Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 96 8 1166 1169 10.1038/sj.bjc.6603685 17375050 10.1038/sj.bjc.6603685 1:CAS:528:DC%2BD2sXkt1Gqsbs%3D (Pubitemid 46625066)
19. E Susman 2004 Rash correlates with tumour response after cetuximab Lancet Oncol 5 11 647 15536688 10.1016/S1470-2045(04)01627-4 (Pubitemid 40267843)
20. CS Karapetis S Khambata-Ford DJ Jonker CJ O'Callaghan D Tu NC Tebbutt RJ Simes H Chalchal JD Shapiro S Robitaille TJ Price L Shepherd HJ Au C Langer MJ Moore JR Zalcberg 2008 K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 17 1757 1765 10.1056/NEJMoa0804385 18946061 10.1056/NEJMoa0804385 1:CAS:528:DC%2BD1cXht12nu77J
21. A Lievre JB Bachet D Le Corre V Boige B Landi JF Emile JF Cote G Tomasic C Penna M Ducreux P Rougier F Penault-Llorca P Laurent-Puig 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 8 3992 3995 10.1158/0008-5472.CAN-06-0191 16618717 10.1158/0008-5472.CAN-06-0191 1:CAS:528:DC%2BD28XjsFSlsb0%3D
22. M Orditura F De Vita G Galizia E Lieto L Vecchione F Vitiello E Martinelli F Ciardiello 2009 Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis Oncol Rep 21 4 1023 1028 19288004 10.3892/or-00000319 1:CAS:528:DC%2BD1MXksVSrt7g%3D
23. K Klinghammer M Knodler A Schmittel V Budach U Keilholz I Tinhofer 2010 Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment Clin Cancer Res 16 1 304 310 10.1158/1078-0432. CCR-09-1928 20028750 10.1158/1078-0432.CCR-09-1928 1:CAS:528:DC%2BC3cXot1Sg
24. M Scartozzi E Galizia S Chiorrini R Giampieri R Berardi C Pierantoni S Cascinu 2009 Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab Ann Oncol 20 2 227 230 10.1093/annonc/mdn637 18842611 10.1093/annonc/mdn637 1:STN:280:DC%2BD1M7jtlWltg%3D%3D
25. O Rixe B Billemont H Izzedine 2007 Hypertension as a predictive factor of Sunitinib activity Ann Oncol 18 6 1117 10.1093/annonc/mdm184 17586751 10.1093/annonc/mdm184 1:STN:280:DC%2BD2szntFGrtg%3D%3D (Pubitemid 47050505)
26. A Wick N Schafer N Dorner D Schemmer M Platten M Bendszus W Wick 2010 Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome J Neurooncol 97 1 157 158 10.1007/s11060-009-0003-5 19727565 10.1007/s11060-009-0003-5 1:STN:280:DC%2BC3c%2FmsV2muw%3D%3D
27. DW Miles A Chan LY Dirix J Cortes X Pivot P Tomczak T Delozier JH Sohn L Provencher F Puglisi N Harbeck GG Steger A Schneeweiss AM Wardley A Chlistalla G Romieu 2010 Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 20 3239 3247 10.1200/JCO.2008.21.6457 20498403 10.1200/JCO.2008.21.6457 1:CAS:528: DC%2BC3cXhtVajur3P
28. M Reck J von Pawel P Zatloukal R Ramlau V Gorbounova V Hirsh N Leighl J Mezger V Archer N Moore C Manegold 2009 Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL J Clin Oncol 27 8 1227 1234 10.1200/JCO.2007.14.5466 19188680 10.1200/JCO.2007.14.5466 1:CAS:528: DC%2BD1MXktFKhsL0%3D
29. NJ Robert V Dieras J Glaspy A Brufsky I Bondarenko O Lipatov E Perez D Yardley X Zhou S Phan 2009 RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695 (suppl; abstr 1005)
30. B Escudier J Bellmunt S Negrier E Bajetta B Melichar S Bracarda A Ravaud S Golding S Jethwa V Sneller 2010 Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 13 2144 2150 10.1200/JCO.2009.26. 7849 20368553 10.1200/JCO.2009.26.7849 1:CAS:528:DC%2BC3cXpsFSgsbo%3D
31. H Hurwitz PS Douglas JP Middleton GW Sledge DH Johnson DA Reardon D Chen O Rosen 2010 Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV) J Clin Oncol 28 15s (suppl: abstr 3039)
32. A Grothey MM Sugrue DM Purdie W Dong D Sargent E Hedrick M Kozloff 2008 Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 33 5326 5334 10.1200/JCO.2008.16.3212 18854571 10.1200/JCO.2008.16.3212 1:CAS:528:DC%2BD1MXhslCmtw%3D%3D
33. JC Yang L Haworth RM Sherry P Hwu DJ Schwartzentruber SL Topalian SM Steinberg HX Chen SA Rosenberg 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 5 427 434 10.1056/NEJMoa021491 12890841 10.1056/NEJMoa021491 1:CAS:528:DC%2BD3sXms1Klu7w%3D (Pubitemid 36910021)